LONDON - Aptamer Group PLC (AIM: APTA), a developer of novel Optimer® binders for the life sciences industry, has disclosed a significant share purchase by its CEO, Dr. Arron Tolley. The transaction took place today on the London Stock Exchange (LON:LSEG), where Dr. Tolley acquired 1,446,759 ordinary shares at a price of 0.3456 pence per share.
Following this purchase, Dr. Tolley's total beneficial interest in Aptamer has increased to 23,240,959 ordinary shares. This represents approximately 1.2% of the company's issued share capital. The acquisition is in line with the UK Market Abuse Regulation, which mandates detailed public disclosure of share transactions by individuals in managerial positions.
The purchase by the CEO is an initial notification and has been formally announced by the company in compliance with market regulation requirements. The identification code for the ordinary shares involved in the transaction is GB00BNRRP542.
Aptamer Group PLC is known for its work in developing Optimer® binders, which are designed to facilitate advancements in various applications within the life sciences sector. The company's shares are traded on the AIM market of the London Stock Exchange.
This transaction may be of interest to investors as an indicator of confidence by the company's leadership in its future prospects. It is not uncommon for executives to purchase shares in their own companies as a sign of commitment and belief in the company's value and potential growth.
The information regarding this transaction is based on a press release statement from Aptamer Group PLC.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.